Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30417394 | 1.00 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL19994756 | 1.00 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL20007994 | 1.00 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL19994746 | 1.00 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL30417062 | 1.00 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 | |
| SCHEMBL19994732 | 0.92 | TRPV4 (1.00) | TRPV4 | |
| SCHEMBL30417167 | 0.84 | TRPV4 (1.00) | TRPV4 | |
| SCHEMBL19995204 | 0.84 | TRPV4 (1.00) | TRPV4 | |
| SCHEMBL23141099 | 0.83 | TRPV4 (1.00) | TRPV4 | |
| SCHEMBL20007517 | 0.83 | TRPV4 (1.00) | TRPV4CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590077-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | claimed |
| EP-3515889-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-07-31 | — | — | EP | claimed |
| US-20190202784-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-04 | — | — | US | claimed |
| WO-2018055527-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | claimed |
| WO-2023213801-A1 | PRE-TARGETING | PRECIRIX N.V. (BE) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023203135-A1 | IMPROVED RADIOLABELLED ANTIBODY | PRECIRIX N.V. (BE) | 2023-10-26 | — | — | WO | disclosed |
| US-20230340111-A1 | ANTIBODY FRAGMENT AGAINST FOLR1 | PRECIRIX N.V. (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4178982-A1 | ANTIBODY FRAGMENT AGAINST FOLR1 | Precirix N.V. (BE) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022013225-A1 | ANTIBODY FRAGMENT AGAINST FOLR1 | PRECIRIX N.V. (BE) | 2022-01-20 | — | — | WO | disclosed |
| US-10590077-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-3515889-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-20190202784-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-20190202784-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018055527-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018055527-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202784-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP3A4 1185/4885KCNH2 305/4885 |
| US-10590077-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885CYP3A4 1185/4885KCNH2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.